{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:41:59Z","timestamp":1788957719913,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,30]]},"DOI":"10.7759\/cureus.85083","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T13:12:48Z","timestamp":1748610768000},"source":"Crossref","is-referenced-by-count":1,"title":["Tomotherapy With Synchrony Fiducial Tracking for Stereotactic Body Radiotherapy in Prostate Cancer: A Single-Center Experience on Toxicity"],"prefix":"10.7759","author":[{"given":"Lorella","family":"Lo Conte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Iorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida Rosalia","family":"Scognamiglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ersilia","family":"Donda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonsina","family":"Pepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Viggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"Francomacaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivona","family":"Zlatkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"NCCN guidelines. prostate cancer version 1.2025. (2024). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000002854","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline","volume":"208","author":"Eastham JA","year":"2022","unstructured":"Eastham JA, Boorjian SA, Kirkby E. Clinically localized prostate cancer: AUA\/ASTRO guideline. J Urol. 2022, 208:505-7. 10.1097\/JU.0000000000002854","journal-title":"J Urol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford P","year":"2024","unstructured":"Cornford P, van den Bergh RC, Briers E, et al.. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024, 86:148-63. 10.1016\/j.eururo.2024.03.027","journal-title":"Eur Urol"},{"key":"ref4","article-title":"Guidelines: Prostate Cancer","author":"Associazione Italiana Oncologia Medica","year":"2024","unstructured":"Associazione Italiana Oncologia Medica. Guidelines: Prostate Cancer. 2024."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01097","article-title":"Hypofractionated radiation therapy for localized prostate cancer: an ASTRO, ASCO, and AUA evidence-based guideline","volume":"36","author":"Morgan SC","year":"2018","unstructured":"Morgan SC, Hoffman K, Loblaw DA, et al.. Hypofractionated radiation therapy for localized prostate cancer: an ASTRO, ASCO, and AUA evidence-based guideline. J Clin Oncol. 2018, 36:JCO1801097. 10.1200\/JCO.18.01097","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.1972","article-title":"Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer","volume":"31","author":"Pollack A","year":"2013","unstructured":"Pollack A, Walker G, Horwitz EM, et al.. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol. 2013, 31:3860-8. 10.1200\/JCO.2013.51.1972","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30070-5","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Incrocci L","year":"2016","unstructured":"Incrocci L, Wortel RC, Alemayehu WG, et al.. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2016, 17:1061-9. 10.1016\/S1470-2045(16)30070-5","journal-title":"Lancet Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.09.078","article-title":"Stereotactic body radiotherapy for primary management of early-stage, low- to intermediate-risk prostate cancer: report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee","volume":"76","author":"Buyyounouski MK","year":"2010","unstructured":"Buyyounouski MK, Price RA Jr, Harris EE, et al.. Stereotactic body radiotherapy for primary management of early-stage, low- to intermediate-risk prostate cancer: report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee. Int J Radiat Oncol Biol Phys. 2010, 76:1297-304. 10.1016\/j.ijrobp.2009.09.078","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/s0360-3016(01)02664-5","article-title":"Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha\/beta ratio), similar to late-responding normal tissue","volume":"52","author":"Brenner DJ","year":"2002","unstructured":"Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha\/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 2002, 52:6-13. 10.1016\/s0360-3016(01)02664-5","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.10.075","article-title":"Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: \u03b1\/\u03b2 = 1.4 (0.9-2.2) Gy","volume":"82","author":"Miralbell R","year":"2012","unstructured":"Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: \u03b1\/\u03b2 = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys. 2012, 82:e17-24. 10.1016\/j.ijrobp.2010.10.075","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2008.04.051","article-title":"Intrafractional motion of the prostate during hypofractionated radiotherapy","volume":"72","author":"Xie Y","year":"2008","unstructured":"Xie Y, Djajaputra D, King CR, Hossain S, Ma L, Xing L. Intrafractional motion of the prostate during hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2008, 72:236-46. 10.1016\/j.ijrobp.2008.04.051","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2008.01.004","article-title":"Reduction of prostate motion by removal of gas in rectum during radiotherapy","volume":"72","author":"Ogino I","year":"2008","unstructured":"Ogino I, Uemura H, Inoue T, Kubota Y, Nomura K, Okamoto N. Reduction of prostate motion by removal of gas in rectum during radiotherapy. Int J Radiat Oncol Biol Phys. 2008, 72:456-66. 10.1016\/j.ijrobp.2008.01.004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.11.054","article-title":"Observations on real-time prostate gland motion using electromagnetic tracking","volume":"71","author":"Langen KM","year":"2008","unstructured":"Langen KM, Willoughby TR, Meeks SL, Santhanam A, Cunningham A, Levine L, Kupelian PA. Observations on real-time prostate gland motion using electromagnetic tracking. Int J Radiat Oncol Biol Phys. 2008, 71:1084-90. 10.1016\/j.ijrobp.2007.11.054","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/0167-8140(95)01613-l","article-title":"Prostate motion during standard radiotherapy as assessed by fiducial markers","volume":"37","author":"Crook JM","year":"1995","unstructured":"Crook JM, Raymond Y, Salhani D, Yang H, Esche B. Prostate motion during standard radiotherapy as assessed by fiducial markers. Radiother Oncol. 1995, 37:35-42. 10.1016\/0167-8140(95)01613-l","journal-title":"Radiother Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1120\/jacmp.v17i2.5836","article-title":"Simultaneous MV-kV imaging for intrafractional motion management during volumetric-modulated arc therapy delivery","volume":"17","author":"Hunt MA","year":"2016","unstructured":"Hunt MA, Sonnick M, Pham H, et al.. Simultaneous MV-kV imaging for intrafractional motion management during volumetric-modulated arc therapy delivery. J Appl Clin Med Phys. 2016, 17:473-86. 10.1120\/jacmp.v17i2.5836","journal-title":"J Appl Clin Med Phys"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark A","year":"2019","unstructured":"Widmark A, Gunnlaugsson A, Beckman L, et al.. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019, 394:385-5. 10.1016\/S0140-6736(19)31131-6","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand DH","year":"2019","unstructured":"Brand DH, Tree AC, Ostler P, et al.. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2019, 20:1531-43. 10.1016\/S1470-2045(19)30569-8","journal-title":"Lancet Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree AC","year":"2022","unstructured":"Tree AC, Ostler P, van der Voet H, et al.. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2022, 23:1308-20. 10.1016\/S1470-2045(22)00517-4","journal-title":"Lancet Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2021.01.010","article-title":"Clinical implementation and initial experience of real-time motion tracking with jaws and multileaf collimator during helical tomotherapy delivery","volume":"11","author":"Chen GP","year":"2021","unstructured":"Chen GP, Tai A, Puckett L, et al.. Clinical implementation and initial experience of real-time motion tracking with jaws and multileaf collimator during helical tomotherapy delivery. Pract Radiat Oncol. 2021, 11:e486-95. 10.1016\/j.prro.2021.01.010","journal-title":"Pract Radiat Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-024-02363-y","article-title":"Implant geometry and detection rates of prostate fiducial markers after transrectal ultrasound-guided perineal implantation for image-guided 6D-tracking in robotic stereotactic body radiotherapy","author":"Gr\u00fcn A","year":"2025","unstructured":"Gr\u00fcn A, Heil K, Zips D, Kalinauskaite G, B\u00f6hmer D. Implant geometry and detection rates of prostate fiducial markers after transrectal ultrasound-guided perineal implantation for image-guided 6D-tracking in robotic stereotactic body radiotherapy. Strahlenther Onkol. 2025, 10.1007\/s00066-024-02363-y","journal-title":"Strahlenther Onkol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.40778","article-title":"Stereotactic body radiation therapy for prostate cancer using TomoTherapy with Synchrony fiducial tracking","volume":"15","author":"Shintani T","year":"2023","unstructured":"Shintani T, Anami S, Sano K, Okada W, Tanooka M. Stereotactic body radiation therapy for prostate cancer using TomoTherapy with Synchrony fiducial tracking. Cureus. 2023, 15:e40778. 10.7759\/cureus.40778","journal-title":"Cureus"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/acm2.13395","article-title":"Stereotactic body radiotherapy using a hydrogel spacer for localized prostate cancer: a dosimetric comparison between tomotherapy with the newly-developed tumor-tracking system and cyberknife","volume":"22","author":"Manabe Y","year":"2021","unstructured":"Manabe Y, Hashimoto S, Mukouyama H, Shibamoto Y. Stereotactic body radiotherapy using a hydrogel spacer for localized prostate cancer: a dosimetric comparison between tomotherapy with the newly-developed tumor-tracking system and cyberknife. J Appl Clin Med Phys. 2021, 22:66-72. 10.1002\/acm2.13395","journal-title":"J Appl Clin Med Phys"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1017\/S1460396922000061","article-title":"Dosimetric comparison of Synchrony\u00ae real-time motion tracking treatment plans between CyberKnife robotic radiosurgery and Radixact system for stereotactic body radiation therapy of lung and prostate cancer","volume":"22","author":"Kong CW","year":"2023","unstructured":"Kong CW, Chiu TL, Geng H, Lam WW, Yang B, Cheung CW, Yu SK. Dosimetric comparison of Synchrony\u00ae real-time motion tracking treatment plans between CyberKnife robotic radiosurgery and Radixact system for stereotactic body radiation therapy of lung and prostate cancer. J Radiother Pract. 2023, 22:e37. 10.1017\/S1460396922000061","journal-title":"J Radiother Pract"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.8006","article-title":"Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer","volume":"2","author":"Kishan AU","year":"2019","unstructured":"Kishan AU, Dang A, Katz AJ, et al.. Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer. JAMA Netw Open. 2019, 2:e188006. 10.1001\/jamanetworkopen.2018.8006","journal-title":"JAMA Netw Open"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/356660-tomotherapy-with-synchrony-fiducial-tracking-for-stereotactic-body-radiotherapy-in-prostate-cancer-a-single-center-experience-on-toxicity","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T13:12:49Z","timestamp":1748610769000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/356660-tomotherapy-with-synchrony-fiducial-tracking-for-stereotactic-body-radiotherapy-in-prostate-cancer-a-single-center-experience-on-toxicity"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.85083","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,30]]}}}